期刊文献+

卵巢癌化疗现状和进展 被引量:7

下载PDF
导出
摘要 卵巢癌是目前死亡率较高的妇科肿瘤之一。由于缺少有效的早期筛查方法,当患者出现明显症状时,疾病多已处于晚期。目前卵巢癌的标准治疗方案以手术为主、术后化疗为辅的联合治疗,手术目的是尽可能切除肿瘤灶,使残余肿瘤灶最大直径<1cm ,以实现满意肿瘤细胞减灭术。卵巢癌对化疗较敏感,即使已广泛转移也能取得一定疗效,既可预防复发,也可用于手术未能全部切净者,使肿瘤体积缩小,为以后手术创造条件,是最重要的辅助治疗手段。
作者 郭春燕
出处 《医学理论与实践》 2014年第5期587-589,共3页 The Journal of Medical Theory and Practice
关键词 卵巢癌 化疗 进展
  • 相关文献

参考文献10

  • 1Trimbos JB, Pannar M, Vergote I, et al. ICON I-ACTION trim, two parallel randomized phase II thai of uvant chemo- therapy in patient in early stage ovarian cancer[J]. J Natl Cancer lnst, 2003,95(2) : 105-112.
  • 2Bell J, Brady MF. Young RC, et al. Randomized phase II trial of three versus six cycles of adjuvant car- boplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic On- cology Group study[J]. Gyfiecol Oncol, 2006,102(3) : 432-439.
  • 3Alberts DS, Liu PY, Hannigan EV,et al. Intraperitoneai eis- platin plusintravenous cyclophosphamide versus intravenouseisplatin plus intravenous eyelophospha- mide for stage ]I o- varian cancer[J] New Ensl J Med, 1996,335(26) : 1950-1955.
  • 4Armstrong DK, Bundy B, Weel L, et al. Intraperitoneai cispla- tin and paclitaxel in ovarian cancer[J]. New Ensl J Mad, 2006, 354 34-43.
  • 5Bookman MA, Brady MF, McGuire WP, et al. Evaiuation of new platinumbased treatment regimens in advanced- stage o- varian cancer: a phase 1I trial of the gynecologic cancer inter- group[J]. J Clin Oncol,2009,27(9) : 1419-1425.
  • 6Cheng WF, Huang CY, Chang MC, et al. High mesothelincor- relates with chemoresistance and poor survival in pithelialovar- ian careinoma[J]. Br J Cancer, 2009,100(7) : 1144-1153.
  • 7Misset JL, Bleiberg H, et al. Oxaliplatin clinical activity: a re- view[J]. Crit Rev Oncol Hematol, 2000,35 : 75-93.
  • 8Poveda A,Vergote I, Tjulandin S, et al. Trabectedin plus pe- gylated liposomal doxorubicin in relapsed ovarian cancer: out- comes in the partially platinum-sensitive (platinum-free inter- va16-12 months) subpopulation of OVA-301 phase HI random- ized trial[J]. Ann Oncol, 2011,22 (1) : 39-48.
  • 9Moretti P,Gadducci A, et al. The concomitant dete-rmination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients[J] Gynecol Oncol, 1992,44:155-160.
  • 10董丽,李小平,崔恒,王建六,魏丽惠,赵彦,王世军,王悦,孙秀丽,梁旭东,李艺.卵巢上皮性癌血清肿瘤标志物谱变化的临床意义[J].中华妇产科杂志,2009,44(2):121-125. 被引量:7

二级参考文献18

  • 1陈洁,刘鸣,汤春生.人卵巢癌细胞系具有不同转移潜能亚系的分离及体内和体外鉴定[J].实用妇产科杂志,2005,21(6):350-352. 被引量:8
  • 2Ovarian cancer: screening, treatment, and followup. NIH Consens Statement, 1994, 12 : 1-30.
  • 3Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer, 2007,17:21-31.
  • 4Cheung VG, Conlin LK, Weber TM, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet ,2003,33:422-425.
  • 5Tuxen MK, Soletormos G, Petersen PH, et al. Assessment of biological variation and analytical imprecision of CA125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol, 1999,74 : 12-22.
  • 6Berchuck A, O1t GJ, Soisson AP, et al. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol, 1990,162:883-888.
  • 7Tangjitgamol S, See HT, Manusirivithaya S, et al. Third-line chemotherapy in platinum- and paelitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Caneer,2004 ,14 :804-814.
  • 8Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA125 : a North Thames Ovary Group study. Ann Oncol, 1996, 7:361-364.
  • 9Fioretti P, Gadducci A, Ferdeghini M, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol, 1992,44 : 155-160.
  • 10Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005,99:267-277.

共引文献6

同被引文献68

引证文献7

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部